Production (Stage)
Adverum Biotechnologies, Inc.
ADVM
$2.21
-$0.02-0.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -73.20% | -111.16% | 17.49% | 41.36% | 6.57% |
| Total Depreciation and Amortization | -31.49% | -19.72% | -41.02% | -37.68% | -37.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -38.02% | 121.04% | -69.61% | -54.84% | 7.05% |
| Change in Net Operating Assets | 108.60% | 330.86% | 187.00% | -187.65% | -83,433.33% |
| Cash from Operations | -84.00% | -32.45% | 11.66% | 14.65% | -3.72% |
| Capital Expenditure | -144.44% | 68.23% | 55.35% | 55.56% | -5.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 243.59% | 57.38% | -170.22% | -103.45% | -201.48% |
| Cash from Investing | 242.01% | 57.59% | -173.34% | -103.47% | -202.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -1.24% | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 43.98% | 100.00% | -1,550.00% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -115.40% | -3.73% | -492.17% | -150.90% | 8,587.83% |